Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [30]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13789 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB4 Monoclonal Antibody (HFR1)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-13789 targets HER-4 in IHC applications and shows reactivity with Human and mouse samples. The MA5-13789 immunogen is a synthetic peptide corresponding to aa 1249-1264 (Cys-RSTLQHPDYLQEYST) from the human c-erbB-4/HER-4 oncoprotein.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- HFR1
- Vial size
- 500 μL
- Concentration
- 0.2 mg/mL
- Storage
- 4°C
Submitted references Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Expression of the epidermal growth factor system in human middle ear cholesteatoma.
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
HER-family gene amplification and expression in resected pancreatic cancer.
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.
Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
Expression of the epidermal growth factor system in human endometrium during the menstrual cycle.
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling.
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
Jerjees DA, Alabdullah M, Green AR, Alshareeda A, Macmillan RD, Ellis IO, Rakha EA
Breast cancer research and treatment 2014 Jun;145(2):317-30
Breast cancer research and treatment 2014 Jun;145(2):317-30
Expression of the epidermal growth factor system in human middle ear cholesteatoma.
Thorup MB, Munk M, Poulsen SS, Gaihede M, Nexo E, Sorensen BS, Ovesen T
Acta oto-laryngologica 2014 Feb;134(2):124-34
Acta oto-laryngologica 2014 Feb;134(2):124-34
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.
Paatero I, Lassus H, Junttila TT, Kaskinen M, Bützow R, Elenius K
Gynecologic oncology 2013 Apr;129(1):179-87
Gynecologic oncology 2013 Apr;129(1):179-87
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, Nam SJ, Bang S, Park J, Kim DH
Breast cancer research : BCR 2010;12(6):R100
Breast cancer research : BCR 2010;12(6):R100
Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH
Diagnostic pathology 2010 Mar 23;5:18
Diagnostic pathology 2010 Mar 23;5:18
HER-family gene amplification and expression in resected pancreatic cancer.
te Velde EA, Franke AC, van Hillegersberg R, Elshof SM, de Weger RW, Borel Rinkes IH, van Diest PJ
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009 Oct;35(10):1098-104
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009 Oct;35(10):1098-104
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA
The breast journal 2009 Mar-Apr;15(2):120-32
The breast journal 2009 Mar-Apr;15(2):120-32
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
Kirkegaard T, Naresh A, Sabine VS, Tovey SM, Edwards J, Dunne B, Cooke TG, Jones FE, Bartlett JM
American journal of clinical pathology 2008 May;129(5):735-43
American journal of clinical pathology 2008 May;129(5):735-43
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE
Cancer research 2008 Aug 1;68(15):6387-95
Cancer research 2008 Aug 1;68(15):6387-95
Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.
Torp SH, Gulati S, Johannessen E, Dalen A
Journal of experimental & clinical cancer research : CR 2007 Sep;26(3):353-9
Journal of experimental & clinical cancer research : CR 2007 Sep;26(3):353-9
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
Sundvall M, Peri L, Määttä JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y, Elenius K
Oncogene 2007 Oct 18;26(48):6905-14
Oncogene 2007 Oct 18;26(48):6905-14
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F
European journal of cancer (Oxford, England : 1990) 2007 Mar;43(4):725-35
European journal of cancer (Oxford, England : 1990) 2007 Mar;43(4):725-35
Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K, Sørensen BS, Poulsen SS, Forman A, Nexø E, Mogensen O
Gynecologic oncology 2007 Jan;104(1):158-67
Gynecologic oncology 2007 Jan;104(1):158-67
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.
Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, Cowan KH, Earp HS 3rd
Molecular and cellular biology 2006 Sep;26(17):6412-24
Molecular and cellular biology 2006 Sep;26(17):6412-24
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH
Pediatric blood & cancer 2006 May 1;46(5):614-23
Pediatric blood & cancer 2006 May 1;46(5):614-23
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO
The Journal of pathology 2006 Mar;208(4):495-506
The Journal of pathology 2006 Mar;208(4):495-506
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jan 1;12(1):123-30
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jan 1;12(1):123-30
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.
Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T
BMC cancer 2006 Feb 28;6:46
BMC cancer 2006 Feb 28;6:46
Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H, Moinfar F
Gynecologic oncology 2006 Apr;101(1):18-23
Gynecologic oncology 2006 Apr;101(1):18-23
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK
Gynecologic oncology 2005 Nov;99(2):415-21
Gynecologic oncology 2005 Nov;99(2):415-21
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
Prentice LM, Shadeo A, Lestou VS, Miller MA, deLeeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG
Oncogene 2005 Nov 10;24(49):7281-9
Oncogene 2005 Nov 10;24(49):7281-9
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG
Cancer 2005 May 1;103(9):1770-7
Cancer 2005 May 1;103(9):1770-7
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H
Breast cancer research and treatment 2005 Jul;92(1):1-9
Breast cancer research and treatment 2005 Jul;92(1):1-9
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P
Molecular cancer therapeutics 2005 Feb;4(2):243-55
Molecular cancer therapeutics 2005 Feb;4(2):243-55
Expression of the epidermal growth factor system in human endometrium during the menstrual cycle.
Ejskjaer K, Sørensen BS, Poulsen SS, Mogensen O, Forman A, Nexø E
Molecular human reproduction 2005 Aug;11(8):543-51
Molecular human reproduction 2005 Aug;11(8):543-51
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO
British journal of cancer 2004 Oct 18;91(8):1532-42
British journal of cancer 2004 Oct 18;91(8):1532-42
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M
Breast (Edinburgh, Scotland) 2004 Aug;13(4):347-9
Breast (Edinburgh, Scotland) 2004 Aug;13(4):347-9
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Adélaïde J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ, Popovici C, Ginestier C, Letessier A, Basset C, Courtay-Cahen C, Jacquemier J, Theillet C, Birnbaum D, Edwards PA, Chaffanet M
Genes, chromosomes & cancer 2003 Aug;37(4):333-45
Genes, chromosomes & cancer 2003 Aug;37(4):333-45
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling.
Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I
Genes & development 2002 Feb 1;16(3):307-23
Genes & development 2002 Feb 1;16(3):307-23
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
Lammering G, Valerie K, Lin PS, Mikkelsen RB, Contessa JN, Feden JP, Farnsworth J, Dent P, Schmidt-Ullrich RK
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Mar;7(3):682-90
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Mar;7(3):682-90
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast cancer stained with c-erbB-4 antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic and membrane staining of tumor cells.
